Alexion Pharmaceuticals reports that children treated with Strensiq experienced significant healing of HPP-related skeletal manifestations and improvements in physical function within three to six months from treatment onset, which were sustained through five years of treatment.

HPP (hypophosphatasia) is a genetic and progressive metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million in the general population.